Cited 2 times in
Prognostic value of complete metabolic response on ¹⁸F-FDG-PET/CT after three cycles of neoadjuvant chemotherapy in advanced high-grade serous ovarian cancer
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 강원준 | - |
dc.contributor.author | 김상운 | - |
dc.contributor.author | 김성훈 | - |
dc.contributor.author | 이정윤 | - |
dc.contributor.author | 정영신 | - |
dc.date.accessioned | 2022-12-22T02:03:47Z | - |
dc.date.available | 2022-12-22T02:03:47Z | - |
dc.date.issued | 2022-05 | - |
dc.identifier.issn | 2005-0380 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/191441 | - |
dc.description.abstract | Objective: We investigated the prognostic value of complete metabolic response (CMR) on ¹⁸F-fluorodeoxyglucose positron emission tomography/computed tomography (¹⁸F-FDG-PET/CT) after 3 cycles of neoadjuvant chemotherapy (NAC) in advanced high-grade serous ovarian cancer (HGSC). Methods: PET/CT at baseline and after 3 cycles of NAC were performed; peak standardized uptakes were measured. PET parameters were compared with NAC parameter: cancer antigen-125 (CA-125) normalization before interval debulking surgery (IDS) and chemotherapy response score (CRS) to predict platinum-sensitivity. Kaplan-Meier analysis was used to determine correlations between PET parameters and survival. Prognostic factors were obtained by multivariate Cox regression analysis. Results: Between 2007 and 2020, 102 patients were recruited: 19 (18.6%) were designated as CMR group and 83 (81.4%) as non-CMR group. CMR after 3 cycles of NAC showed the highest accuracy in predicting platinum-sensitivity (area under the curve [AUC]=0.729; 95% confidence interval [CI]=0.552-0.823; p=0.017), compared with CA-125 normalization before IDS (AUC=0.626; 95% CI=0.542-0.758; p=0.010) and CRS (AUC=0.613; 95% CI=0.490-0.735; p=0.080). CMR demonstrated better prognosis than non-CMR in progression-free survival (PFS) (median PFS, 23.9 months vs. 16.4 months; p=0.021) and overall survival (OS) (median OS, not reached vs. 69.7 months; p=0.025). In multivariate analysis, CMR was associated with a lower risk of recurrence (adjusted hazard ratio [aHR]=0.50; 95% CI=0.27-0.92; p=0.027) and death (aHR=0.23; 95% CI=0.05-0.99; p=0.048). Conclusion: CMR after 3 cycles of NAC can be a prognostic factor for both recurrence and death in advanced HGSC. | - |
dc.description.statementOfResponsibility | open | - |
dc.language | English | - |
dc.publisher | Asian Society of Gynecologic Oncology : Taehan Puin Chongyang Hakhoe | - |
dc.relation.isPartOf | JOURNAL OF GYNECOLOGIC ONCOLOGY | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Fluorodeoxyglucose F18* | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Neoadjuvant Therapy / methods | - |
dc.subject.MESH | Ovarian Neoplasms* / diagnostic imaging | - |
dc.subject.MESH | Ovarian Neoplasms* / drug therapy | - |
dc.subject.MESH | Positron Emission Tomography Computed Tomography / methods | - |
dc.subject.MESH | Prognosis | - |
dc.subject.MESH | Radiopharmaceuticals | - |
dc.subject.MESH | Retrospective Studies | - |
dc.title | Prognostic value of complete metabolic response on ¹⁸F-FDG-PET/CT after three cycles of neoadjuvant chemotherapy in advanced high-grade serous ovarian cancer | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Nuclear Medicine (핵의학교실) | - |
dc.contributor.googleauthor | Young Shin Chung | - |
dc.contributor.googleauthor | Yup Kim | - |
dc.contributor.googleauthor | Hyun-Soo Kim | - |
dc.contributor.googleauthor | Jung-Yun Lee | - |
dc.contributor.googleauthor | Won Jun Kang | - |
dc.contributor.googleauthor | Sunghoon Kim | - |
dc.contributor.googleauthor | Sang Wun Kim | - |
dc.identifier.doi | 10.3802/jgo.2022.33.e28 | - |
dc.contributor.localId | A00062 | - |
dc.contributor.localId | A00526 | - |
dc.contributor.localId | A00595 | - |
dc.contributor.localId | A04638 | - |
dc.contributor.localId | A04849 | - |
dc.relation.journalcode | J01428 | - |
dc.identifier.eissn | 2005-0399 | - |
dc.identifier.pmid | 35128858 | - |
dc.subject.keyword | Neoadjuvant Therapy | - |
dc.subject.keyword | Ovarian Neoplasms | - |
dc.subject.keyword | Positron Emission Tomography Computed Tomography | - |
dc.subject.keyword | Prognosis | - |
dc.contributor.alternativeName | Kang, Won Jun | - |
dc.contributor.affiliatedAuthor | 강원준 | - |
dc.contributor.affiliatedAuthor | 김상운 | - |
dc.contributor.affiliatedAuthor | 김성훈 | - |
dc.contributor.affiliatedAuthor | 이정윤 | - |
dc.contributor.affiliatedAuthor | 정영신 | - |
dc.citation.volume | 33 | - |
dc.citation.number | 3 | - |
dc.citation.startPage | e28 | - |
dc.identifier.bibliographicCitation | JOURNAL OF GYNECOLOGIC ONCOLOGY, Vol.33(3) : e28, 2022-05 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.